BridgeBio turns Alexion asset into first approved drug for rare metabolic disease March 1, 2021 Auto Bot BioPharma, biopharma nl, California, FDA, palo alto, Pharma, Rare diseases 0 The FDA decision makes Nulibry the first drug approved to treat MoCD type A, a rare metabolic disease. It’s also the first FDA-approved product for rare disease drug developer BridgeBio Pharma.